MedPath

Safety of the new H1N1 influenza vaccine in pregnancy

Conditions
new influenza A(H1N1), spontaneous abortion, preeclampsia, preterm birth, intrauterine growth restriction, congenital disorders
Registration Number
DRKS00000318
Lead Sponsor
Paul-Ehrlich-Institut PEIAbteilung Sicherheit von Arzneimitteln und Medizinprodukten
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
1652
Inclusion Criteria

1. Live in Germany
2. Vaccinated with new H1N1 vaccine during pregnancy or just before

Exclusion Criteria

Other suspicious drugs during pregnancy or just before

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Possible adverse effects on pregnancy and possible teratogenic effects of the new H1N1 vaccine evaluated in terms of the rate of spontaneous abortion, preeclampsia, preterm birth, intrauterine growth restriction, congenital disorders.
Secondary Outcome Measures
NameTimeMethod
Influence of the time of vaccination on the primary outcome
© Copyright 2025. All Rights Reserved by MedPath